NCT00079794CompletedPhase 2
Iscar for Supplemental Care in Stage IV Lung Cancer
National Center for Complementary and Integrative Health (NCCIH)2 sites in 1 country36 target enrollmentStarted: September 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 36
- Locations
- 2
Study Overview
Brief Summary
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.
Detailed Description
See Brief Summary
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Stage IV NSCLC patients who receive standard chemotherapy
- •Exclusion criteria:
- •Known allergy to Viscum Album L.
- •Concomitant use of other mistletoe products
- •Concomitant use of mushroom glucan and proteoglycan extracts
- •Concomitant use of thymus extract products
- •Inability to self-report quality of life utilizing assessment tools
- •Ongoing steroid or ACTH therapy
- •Co-morbid immunocompromised state
- •Pregnancy
- •Participation in other clinical trials
Exclusion Criteria
- Not provided
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00283478Kentuckiana Cancer Institute20
Completed
Phase 2
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung CancerLung CancerNCT00601796H. Lee Moffitt Cancer Center and Research Institute24
Recruiting
Not Applicable
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric CancerStage III Gastric CancerNCT05253716Jinling Hospital, China696
Terminated
Phase 1
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung CancerLung Cancer, Non-Small CellNCT00455572GlaxoSmithKline71
Terminated
Phase 2
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerInoperable œsophageal CancerNCT03437200European Organisation for Research and Treatment of Cancer - EORTC8